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Altered insulin signaling and neuroinflammation are emerging features of Alzheimer’s disease. Lourenco et al.
(2013) identify a pathogenic mechanism that is shared between Alzheimer’s disease and diabetes and
contributes to memory loss through a common molecular event: the control of protein synthesis by PKR
and the downstream phosphorylation of eIF2a.Alzheimer’s disease (AD) is the most
common cause of dementia, affecting
one in eight individuals over 65 years in
the US. The accumulation of b-amyloid
(Ab) oligomers and amyloid plaques in
the cerebral cortex and hippocampus is
thought to underlie synaptic dysfunction
and neuronal death, leading to cognitive
impairment and memory loss in AD
(Cornejo and Hetz, 2013; Holtzman
et al., 2011). Thus, it is of paramount
importance to define the age-related
factors responsible for the burden of Ab
peptides. An emerging concept suggests
that AD may be viewed as a form of dia-
betes in the brain (Bomfim et al., 2012).
Recently, Bomfim et al. (2012) described
the beneficial effects of administering
exendin-4, an FDA-approved antidiabetic
agent, in a transgenicmousemodel of AD.
In the study, exendin-4 treatment cor-
rected insulin resistance and improved
cognitive deficits in the AD mice (Bomfim
et al., 2012). Insulin signaling in the brain
orchestrates energy balance through the
concerted action on different brain cir-
cuits, ranging from control of appetite
in the hypothalamus to consolidation of
learning and memory in the hippocampus
(Fernandez and Torres Alema´n, 2012). In
this way, it appears that peripheral organs
and the nervous system share common
mechanisms of metabolic regulation,
and hence, molecular events associated
with metabolic disorders may also partic-
ipate in neurodegenerative cascades.
In this issue, Lourenco et al. (2013) shed
light on the connection between AD and
diabetes by reporting that Ab oligomerscause impaired insulin signaling and
memory deficits through a mechanism
involving tumor necrosis factor alpha
(TNF-a) and downstream activation of
the protein kinase R (PKR) (Lourenco
et al., 2013) (Figure 1).
Over the last century, we have wit-
nessed a dramatic increase in life
expectancy along with many changes in
lifestyle. The metabolic stress triggered
by lack of physical exercise combined
with high calorie intake causes an array
of interconnected health problems, such
as obesity and diabetes. At the molecular
and cellular levels, the increase in energy
availability disrupts the homeostasis of
several organelles, including the endo-
plasmic reticulum (ER) (Hotamisligil,
2010). This leads to an abnormal condi-
tion termed ER stress, characterized by
the accumulation of misfolded proteins
in the ER lumen and activation of a stress
signaling pathway termed the unfolded
protein response (UPR) (Hetz et al.,
2013). The UPR decreases protein
synthesis through PKR-like ER kinase
(PERK)-mediated inhibitory phospho-
rylation of the eukaryotic translation initia-
tion factor 2a (eIF2a). eIF2a phosphoryla-
tion is part of an integrated stress
response that decreases protein transla-
tion of a stressed cell and also induces
downstream transcriptional responses
through the expression of activating tran-
scription factor 4 (ATF4) (Hetz et al.,
2013). Importantly, genetic or pharmaco-
logical inhibition of eIF2a kinases leads
to enhanced synaptic plasticity and
cognitive function in wild-type mice andCell Metabolism 18,transgenic mouse models of AD (Zhu
et al., 2011; Ma et al., 2013), possibly
due to increased expression of a
large cluster of synaptic proteins.
Another eIF2a kinase, termed PKR, is
activated by inflammatory signals and is
involved in learning and memory (Zhu
et al., 2011). Thus, stress adaptation
and memory consolidation converge at
the level of eIF2a phosphorylation, and
aberrantly elevated levels of phospho-
rylated eIF2a are likely involved in AD
pathogenesis.
Lourenco et al. (2013) now examine
in more detail the connection between
AD and diabetes. Using TNF-a/ and
PKR/ mice, they demonstrate that
TNF-a and PKR lie upstream of eIF2a
phosphorylation and establish the
TNF-a/PKR axis as a mechanism of
synapse loss and cognitive impairment
triggered by Ab oligomers. In addition,
they show that ER stress mediates the
inhibitory phosphorylation of insulin re-
ceptor substrate 1 (IRS-1), leading to
impaired insulin signaling in the brain.
Remarkably, insulin treatment reverted
phosphorylation of PKR and eIF2a in
hippocampal neurons. Furthermore, the
administration of antidiabetic agents
(i.e., liraglutide and exendin-4) and chem-
ical chaperones (i.e., 4-phenylbutyrate
[4-PBA], attenuators of ER stress)
reduced phosphorylation of eIF2a and
ER stress levels, increasing synaptic
density and cognitive performance in
animal models of AD (Figure 1). Finally,
liraglutide reduced phospho-eIF2a
levels in nonhuman primates injectedDecember 3, 2013 ª2013 Elsevier Inc. 771
Figure 1. Crosstalk between ER Stress, PKR, Inflammation, and
Insulin Signaling in Alzheimer’s Disease
Accumulation of Ab oligomers (AbOs) leads to production of TNF-a by micro-
glia as well as phosphorylation and activation of PKR in neurons. Active PKR
leads to the inhibition of protein synthesis by phosphorylation of eIF2a. Ab olig-
omers also cause ER stress and eventually insulin resistance due to serine
phosphorylation of insulin receptor substrate 1 (IRS1). ER stress and insulin
resistance feed a vicious cycle, promoting further accumulation of Ab oligo-
mers by JNK3-stimulated processing of amyloid precursor protein (APP) and
inhibition of protein synthesis due to PKR- and PERK-mediated phosphoryla-
tion of eIF2a. The reduction in protein synthesis impairs synaptic plasticity,
leading to memory deficits in AD. Administration of antidiabetic agents
(ADAs) or the chemical chaperone 4-phenylbutyrate (4-PBA) blocks the vicious
cycle and improves cognition in mouse models of AD.
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the clinical relevance of the
study.
Overall, Lourenco et al.
(2013) convincingly convey
the idea that Ab oligomers
exert their neurotoxic activity
by instigating a TNF-a/PKR
signaling pathway, leading to
attenuated protein synthesis
due to sustained phosphory-
lation of eIF2a and insulin
resistance by the phosphory-
lation of IRS-1. Moreover, the
authors provide valuable
mechanistic clues into the
beneficial effects of antidia-
betic drugs in animal models
of AD. Nonetheless, some
specific points remain open
for further investigation.
According to the authors,
microglia likely represent the
source of TNF-a. If so, do Ab
oligomers directly engage
signaling events in microglia
that then connect with the
TNF-a/PKR pathway? What
is the exact mechanism
involved the phosphorylation
of IRS-1 by Ab oligomers?
Regarding the beneficial
action of the antidiabetic
agents, crucial questions
have yet to be answered.
Most important, by which
mechanism do the antidia-betic agents reduce the amount of Ab
oligomers? Are these drugs acting on
neurons, or do they have an unanticipated
action in glial cells? Are the levels of
TNF-a also reduced upon treatment
with these antidiabetic agents? Finally,
although ER stress was shown to induce
IRS-1 inhibition, this effect was inde-
pendent of eIF2a. The contribution of
other UPR signaling branches (i.e., the
IRE1/XBP1 pathway) to the disease pro-
cess remains to be determined in this
context.
The fact that insulin signaling can be
impaired by Ab oligomers and, at
the same time, activated to reduce the
burden of such species, suggests the
occurrence of a feedforward cycle
in which inflammation and metabolic
pathways intersect at the ER, causing772 Cell Metabolism 18, December 3, 2013 ªinhibition of insulin signaling, augmented
production of Ab oligomers, and attenua-
tion of protein synthesis. The outcome of
such detrimental synergism is weakening
of synapses and cognitive deficits that
eventually translate into dementia. Along
these lines, a recent report proposed a
positive feedback loop for sustained
toxicity of Ab oligomers that involves
translational block and c-Jun N-terminal
kinase 3 (JNK3) activation (Yoon et al.,
2012), which enhances the generation of
Ab oligomers. Further accumulation of
these species, in turn, blocks protein
translation by inhibiting the mam-
malian target of rapamycin (mTOR)
complex through the activation of the
metabolic sensor AMP kinase. Altered
protein translation then induces ER
stress and further activation of JNK3,2013 Elsevier Inc.perpetuating a vicious cycle
that eventually leads to cell
demise (Figure 1).
These reports provide
pieces of the same puzzle,
where ER stress is at the
crossroads of inflammation,
metabolic deregulation, and
inhibition of protein transla-
tion (Figure 1). Further studies
targeting proteostasis dis-
turbances should provide
valuable insights into the
contribution of these events
to the pathogenesis of AD.ACKNOWLEDGMENTS
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